Next-generation blood thinners are marketed as easier to use, more convenient, and even safer than warfarin, the old stand-by. But they carry a risk that is not advertised. They can cause uncontrollable bleeding. Until October, 2015, there was no antidote for these medications. Then, Praxbind (idarucizumab) was approved to reverse the effects of … [Read more...]
Xarelto Bellwether Cases Selected
Xarelto multidistrict litigation (MDL) 2592 consolidates more than 2,800 lawsuits against Bayer AG and Janssen Pharmaceuticals. 40 bellwether cases have been selected in the MDL. The bellwether cases are meant to be representative of everything that will be covered in the individual cases. MDL is different from a class action in that the individual … [Read more...]
Makers of Xarelto Accused of Deceiving Top Medical Journal
The popular U.S. drug Xarelto has been the cause of controversy for quite some time now, with over 5,000 lawsuits nationwide, and 500 patient deaths allegedly tied to the drug. More recently, a document emerged, alleging that two major pharmaceutical companies misled medical journals by leaving out critical data on the drug. USRecallNews.com … [Read more...]
Two Significant Developments Concerning Xarelto Litigation
Thousands of lawsuits have recently been filed by victims of the popular anti-blood clotting drug Xarelto, which can lead to uncontrollable bleeding in users due to its lack of a bleeding antidote. Marketed for its “once a day” dosage, the defective drug also poses risks to consumers when its effects wear off during the day or night, leaving … [Read more...]
Drug Makers Routinely Submit Incomplete Reports of Side Effects to FDA
By Sandra Dalton, Staff Writer When researchers analyzed the serious adverse event reports made to the U.S. Food and Drug Administration (FDA) in 2014, they found that reports filed by drug makers were incomplete more than half of the time, while more than 86% of those filed directly by health professional and consumers were complete. The FDA’s … [Read more...]
Recent Comments